Project Grant HT9425261E095
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $840K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- Federal Grant Award Summary Massachusetts General Hospital's Research Management Division received a $839,954 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026 through May 31, 2028. The award funds research on "Augmented Immunomodulatory and Neuroprotective Allogeneic B Cell Therapy for ALS" (amyotrophic lateral sclerosis), a clinical and translational research initiative...
- Federal Grant Award Summary Brigham & Women's Hospital Inc., Department of Faulkner Pathology, received a $266,368 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for research into mechanisms of immune suppression in tuberous sclerosis complex (TSC). The award, effective July 15, 2025, with a completion date of July 14, 2027, funds biomedical research designed to advance medical understanding and develop therapeutic...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a Project Grant award of $864,498 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025, through July 31, 2028. The research initiative, "Targeting Neuroinflammation to Promote Neurological Recovery After Traumatic Spinal Cord Injury," is being conducted at the hospital's Department of Faulkner Pathology location in Boston,...
- The Department of Defense's Defense Health Agency awarded a $1,035,460 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "TREATMENT OF ALS BY NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO MODULATE INFLAMMATORY MICROGLIA AND PREVENT MOTOR NEURON DEGENERATION". This grant, funded under the Military Medical Research and Development program (CFDA 12.420), aims to develop a new treatment approach for amyotrophic lateral sclerosis (ALS) by modulating...
- Federal Grant Award Summary Brigham & Women's Hospital Inc., operating through its Department of Faulkner Pathology, received a $168,042 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective August 1, 2025, with completion scheduled for July 31, 2026. The award supports research focused on in vivo targeting of TFE3 (Transcription Factor E3) dimerization partners in translocation renal cell carcinoma (RCC). This...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $654,273 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period of August 1, 2025, through July 31, 2026. The award supports research focused on variable ventilation strategies to reduce ventilator-induced lung injury (VILI) in acute respiratory distress syndrome (ARDS) patients. This research aims to advance clinical care for...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $939,325 to the Weizmann Institute of Science on November 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) to support the GLOBALS (Global Omic Biomarker Research for ALS) initiative. This three-year project, extending through October 31, 2028, funds advanced biomedical research focused on discovering and developing omic biomarkers for amyotrophic lateral sclerosis (ALS). The research...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded $831,722 through its Military Medical Research and Development program (CFDA 12.420) to Aristotle University of Thessaloniki's Special Account for Research Funds on June 15, 2026, for a two-year project completion deadline of June 14, 2028. The award supports research on oxidized-protein targeted degradation as a first-in-class therapeutic strategy to combat oxidative damage in amyotrophic lateral sclerosis (ALS). This project...
- The Defense Health Agency awarded Brigham & Women's Hospital Inc. a $253,636 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2025 to investigate the role of the secreted factor CTHRC1 in the pathogenesis of tuberous sclerosis complex. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health care...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.1 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026, through May 31, 2030. The project, titled "LISTEN: Augmenting and Facilitating Communication in Brain Tumor Patients with Aphasia," supports biomedical research addressing Service Member health and military-relevant medical conditions. The four-year...